Callan Capital’s Poseida Therapeutics PSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-108,080
Closed -$309K – 374
2024
Q3
$309K Buy
108,080
+24,000
+29% +$74.3K 0.02% 256
2024
Q2
$246K Buy
84,080
+5,500
+7% +$15K 0.02% 262
2024
Q1
$251K Buy
78,580
+2,021
+3% +$6.74K 0.02% 237
2023
Q4
$257K Hold
76,559
– – 0.02% 188
2023
Q3
$182K Buy
76,559
+4,000
+6% +$8.38K 0.02% 192
2023
Q2
$128K Buy
72,559
+4,552
+7% +$11.6K 0.01% 176
2023
Q1
$209K Buy
68,007
+5,660
+9% +$33.9K 0.02% 170
2022
Q4
$330K Buy
+62,347
New +$285K 0.04% 133

Other funds holding PSTX

Callan Capital's PSTX Position: Q4 2024 in Review

Callan Capital sold out of Poseida Therapeutics (PSTX) in Q4 2024, closing a stake of 108,080 shares — an estimated $309K sold.

Callan Capital first reported a position in PSTX in Q4 2022 and held it in 8 quarters. The position peaked at $330K in Q4 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Callan Capital reported no remaining Poseida Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Callan Capital sold 108,080 Poseida Therapeutics shares in Q4 2024, an estimated $309K.
  • Callan Capital first reported a position in Poseida Therapeutics in Q4 2022 and held it in 8 quarters.
  • Callan Capital's Poseida Therapeutics position peaked at $330K in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics as of Q4 2024.

Based on Callan Capital's 13F filing for Q4 2024, filed 3 Feb 2025.